Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542444 | 1.00 | SLC15A1 (0.61) | SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2137609 | 1.00 | SLC15A1 (0.61) | SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL2135391 | 0.98 | SLC15A1 (0.59) | SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL7275901 | 0.98 | SLC15A1 (0.59) | SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL542587 | 0.98 | SLC15A1 (0.59) | SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL2137602 | 0.98 | SLC15A1 (0.59) | SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL7275897 | 0.98 | SLC15A1 (0.59) | SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL28244846 | 0.95 | SLC15A1 (0.60) | SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL28244847 | 0.95 | SLC15A1 (0.60) | SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1 | |
| Lactic Acid SCHEMBL28307486 | 0.94 | SLC15A1 (0.59) | SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 791 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852338-A | Oral micromolecular salvianic acid derivatives, and preparation method and application thereof | 首都医科大学 | 2024-10-29 | — | — | CN | claimed |
| CN-118852337-A | Antitumor drug and preparation method thereof | 广西中医药大学 | 2024-10-29 | — | — | CN | claimed |
| CN-112812149-B | Amino acid derivative, preparation method and application thereof, anti-tumor micelle and preparation method thereof | 首都医科大学 | 2022-04-29 | — | — | CN | claimed |
| CN-111689877-B | High-selectivity mercury ion detection fluorescent probe and synthetic method and application thereof | 商丘师范学院 | 2022-03-25 | — | — | CN | claimed |
| CN-107698660-B | imidazopyridine-6-formyl-Lys (Lys) -oligopeptides, their synthesis, activity and uses | 首都医科大学 | 2021-06-08 | — | — | CN | claimed |
| CN-111689877-A | High-selectivity mercury ion detection fluorescent probe and synthetic method and application thereof | 商丘师范学院 | 2020-09-22 | — | — | CN | claimed |
| CN-106349332-B | imidazopyridinyl-KRGDV, its synthesis, antithrombotic activity and use | 首都医科大学 | 2019-12-10 | — | — | CN | claimed |
| EP-3275864-B1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2019-08-14 | — | — | EP | claimed |
| US-10149841-B2 | Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-12-11 | — | — | US | claimed |
| US-20180117021-A1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | claimed |
| US-20090192318-A1 | Method of preparation of N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-y1) [1,1'-biphenyl]-4-y1]methyl]-L-valine (valsartan) | ZENTIVA, A.S. (CZ) | 2009-07-30 | — | — | US | claimed |
| WO-2008135762-A1 | PROCESS FOR PREPARING VALSARTAN | CIPLA LIMITED (IN) | 2008-11-13 | — | — | WO | claimed |
| WO-2008012852-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS | S.I.M.S. S.r.l. - SOCIETÀ ITALIANA MEDICINALI SCANDICCI (IT) | 2008-01-31 | — | — | WO | claimed |
| US-20060281801-A1 | Process for the preparation of valsartan and its intermediates | IPCA LABORATORIES LIMITED (IN) | 2006-12-14 | — | — | US | claimed |
| EP-1714963-A1 | Process for the Preparation of Valsartan and its Intermediates | IPCA Laboratories Limited (IN) | 2006-10-25 | — | — | EP | claimed |
| EP-1622882-B1 | A METHOD OF PREPARATION OF N -(1-OXOPENTYL)- N-¬¬ 2-(1TETRAZOL-5-y1) ¬1,1 -BIPHENYL|-4-y1 METHYL| -L-VALINE (VALSARTAN) | ZENTIVA AS (CZ) | 2006-07-12 | — | — | EP | claimed |
| EP-1622882-A1 | A METHOD OF PREPARATION OF N -(1-OXOPENTYL)- N-[[ 2-(1TETRAZOL-5-y1) [1,1 -BIPHENYL]-4-y1 METHYL] -L-VALINE (VALSARTAN) | ZENTIVA, A.S. (CZ) | 2006-02-08 | — | — | EP | claimed |
| WO-2004101534-A1 | A METHOD OF PREPARATION OF N-(1-OXOPENTYL)-N-[[2'-(1H-TETRAZOL-5-y1) [1,1'-BIPHENYL] -4-y1]METHYL]-L-VALINE (VALSARTAN) | ZENTIVA, A. S. (CZ) | 2004-11-25 | — | — | WO | claimed |
| US-5602161-A | ELASTASE INHIBITORS; PREVENTING AND TREATING EMPHYSEMA, ENDOTOXIN-INDUCED LUNG DISORDERS | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-11 | — | — | US | claimed |
| EP-0676396-A1 | Tetrazolylphenyl pivalate derivatives and medicinal composition containing the same as effective component | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1995-10-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281801-A1 | Process for the preparation of valsartan and its intermediates | ACE, REN, AGT | SLC15A1 1529/4885ALDH1A1 934/4885SLC1A3 2463/4885 |
| US-20090192318-A1 | Method of preparation of N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-y1) [1,1'-biphenyl]-4-y1]methyl]-L-valine (valsartan) | TTR, REN, VARS1 | SLC15A1 2056/4885ALDH1A1 2118/4885SLC1A3 1376/4885 |
| US-20180117021-A1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | EGLN3, EGLN2, P4HA1 | SLC15A1 3223/4885ALDH1A1 243/4885SLC1A3 3012/4885 |
| US-10149841-B2 | Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof | EGLN3, EGLN2, P4HA1 | SLC15A1 3223/4885ALDH1A1 243/4885SLC1A3 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.